PDCD1 and neoplasm: However, similar to other chemotherapeutic treatments, the use of immune checkpoint blockades, such as that for CTLA-4, PD-1, and PD-L1, also develops resistance to some extent, because blocking one pathway often activates the others in the complex network of tumor environments.